Patents by Inventor Wolfgang Haap

Wolfgang Haap has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7868030
    Abstract: Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R3 have the significance given in the application and which can be used in the form of pharmaceutical compositions.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: January 11, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marcel Gubler, Wolfgang Haap, Paul Hebeisen, Eric A. Kitas, Bernd Kuhn, Rudolf E. Minder, Brigitte Schott, Hans P. Wessel
  • Publication number: 20100317647
    Abstract: The invention relates to a compound of formula (I) wherein A1 and R1 to R5 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: June 2, 2010
    Publication date: December 16, 2010
    Inventors: David Banner, Simona M. Ceccarelli, Uwe Grether, Wolfgang Haap, Hans Hilpert, Holger Kuehne, Harald Mauser, Jean-Marc Plancher, Rubén Alvarez Sánchez
  • Patent number: 7820699
    Abstract: The invention is concerned with cyclic amines of formula (I) wherein X1 to X3, Y1 to Y3, R1?, R1? and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit coagulation factor Xa and can be used as medicaments and for treating diseases associated with coagulation factor Xa.
    Type: Grant
    Filed: April 13, 2006
    Date of Patent: October 26, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Narendra Panday, Fabienne Ricklin, Beat Wirz
  • Publication number: 20100267722
    Abstract: The invention relates to a compound of formula (I) wherein A, R1-R6 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: April 16, 2010
    Publication date: October 21, 2010
    Inventors: Rubén Alvarez Sánchez, David Banner, Simona M. Ceccarelli, Uwe Grether, Wolfgang Haap, Peter Hartman, Guido Hartmann, Hans Hilpert, Holger Kuehne, Harald Mauser, Jean-Marc Plancher
  • Patent number: 7731985
    Abstract: A method is provided for the antimicrobial treatment of a surface which comprises the contacting a surface with substituted 4-aminopyrimidines.
    Type: Grant
    Filed: March 10, 2003
    Date of Patent: June 8, 2010
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: Sophie Marquais-Bienewald, Werner Hölzl, Wolfgang Haap, Andrea Preuss, Andreas Mehlin
  • Patent number: 7718679
    Abstract: The invention is concerned with novel heteroaryl carboxamides of formula (I) wherein A, R1, R2, X, Y, Z and m are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used for the treatment or prevention of thrombotic disorders.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: May 18, 2010
    Assignee: Hoffman-La Roche Inc.
    Inventors: Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Bernd Kuhn, Narendra Panday, Fabienne Ricklin
  • Patent number: 7718659
    Abstract: The invention is concerned with novel heteroarylacetamides of formula (I) Rd—C(O)—N(Re)—Rc—CH2—C(O)—N(Ra)(Rb)??(I) wherein Ra to Re are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
    Type: Grant
    Filed: February 4, 2008
    Date of Patent: May 18, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Markus Boehringer, Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Narendra Panday, Fabienne Ricklin
  • Patent number: 7678917
    Abstract: The invention is concerned with novel cycloalkane carboxamides of formula (I) wherein X, X1, Y, Y1, R1?, R1?, R2, R3, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: March 16, 2010
    Assignee: Hoffman-La Roche Inc.
    Inventors: Katrin Gröbke Zbinden, Wolfgang Haap, Hans Hilpert, Narendra Panday, Fabienne Ricklin
  • Publication number: 20090270360
    Abstract: The invention is concerned with novel dicarboxamide derivatives of formula (I) wherein A, B, Rc, D and E are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
    Type: Application
    Filed: January 16, 2009
    Publication date: October 29, 2009
    Inventors: Markus Boehringer, Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Jacques Himber, Roland Humm, Hans Iding, Dietmar Knopp, Narendra Panday, Fabienne Ricklin, Christoph Martin Stahl
  • Patent number: 7601752
    Abstract: The invention is concerned with novel pyrrolidine derivatives of formula (I) wherein X, Y, R1, R2 and R3 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
    Type: Grant
    Filed: November 6, 2006
    Date of Patent: October 13, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lilli Anselm, Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Jacques Himber, Bernd Kuhn, Narendra Panday, Fabienne Ricklin, Stefan Thomi
  • Publication number: 20090215826
    Abstract: The invention is concerned with crystalline forms or amorphous forms of a pyrrolidine-3,4-dicarboxamide derivative, which is useful as an active ingredient of medicaments for the diseases which can be treated by the coagulation factor Xa inhibitors.
    Type: Application
    Filed: February 19, 2009
    Publication date: August 27, 2009
    Inventors: Jean-Michel Adam, Andre Bubendorf, Annette Deynet-Vucenovic, Pascal Dott, Alexander Glomme, Olaf Grassmann, Wolfgang Haap, Martin Kuentz, Roland Meier
  • Patent number: 7576088
    Abstract: The present invention relates to compounds of the general formula and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases such as obesity by selective modulation of CB1 receptors.
    Type: Grant
    Filed: February 22, 2005
    Date of Patent: August 18, 2009
    Assignee: Hoffman-La Roche Inc.
    Inventors: Alexander Alanine, Konrad Bleicher, Wolfgang Guba, Wolfgang Haap, Dagmar Kube, Thomas Luebbers, Jean-Marc Plancher, Olivier Roche, Mark Rogers-Evans, Gisbert Schneider, Jochen Zuegge
  • Patent number: 7550487
    Abstract: The invention is concerned with novel pyrrolidine-3,4-dicarboxamide derivatives of formula (I) wherein R1 to R9 and X are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
    Type: Grant
    Filed: March 9, 2005
    Date of Patent: June 23, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lilli Anselm, Katrin Groebke Zbinden, Wolfgang Haap, Jacques Himber, Christoph Martin Stahl, Stefan Thomi
  • Publication number: 20090143439
    Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof wherein the residues have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.
    Type: Application
    Filed: November 24, 2008
    Publication date: June 4, 2009
    Inventors: Wolfgang Haap, Paul Hebeisen, Eric A. Kitas, Bernd Kuhn, Peter Mohr, Hans Peter Wessel
  • Patent number: 7501413
    Abstract: The invention is concerned with novel dicarboxamide derivatives of formula (I) wherein A, B, Rc, D and E are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
    Type: Grant
    Filed: October 31, 2005
    Date of Patent: March 10, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Markus Boehringer, Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Jacques Himber, Roland Humm, Hans Iding, Dietmar Knopp, Narendra Panday, Fabienne Ricklin, Christoph Martin Stahl
  • Patent number: 7417144
    Abstract: The invention is concerned with novel heteroaryl fused cyclic amines of formula (I) wherein A, X1 to X3, Y1 to Y3, Z, R1, R2, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit coagulation factor Xa and can be used as medicaments.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: August 26, 2008
    Assignee: Hoffman-La Roche Inc.
    Inventors: Markus Boehringer, Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Narendra Panday, Fabienne Ricklin
  • Publication number: 20080146550
    Abstract: The invention is concerned with novel heteroarylacetamides of formula (I) R—C(O)—N(Re)—Rc—CH2—C(O)—N(Ra)(Rb) ??(I) wherein Ra to Re are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
    Type: Application
    Filed: February 4, 2008
    Publication date: June 19, 2008
    Inventors: Markus Boehringer, Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Narendra Panday, Fabienne Ricklin
  • Publication number: 20080103143
    Abstract: The invention is concerned with novel heteroaryl carboxamides of formula (I) wherein A, R1, R2, X, Y, Z and m are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used for the treatment or prevention of thrombotic disorders.
    Type: Application
    Filed: October 19, 2007
    Publication date: May 1, 2008
    Inventors: Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Bernd Kuhn, Narendra Panday, Fabienne Ricklin
  • Patent number: 7361672
    Abstract: The invention is concerned with novel heteroarylacetamides of formula (I) Rd—C(O)—N(Re)—Rc—CH2—C(O)—N(Ra)(Rb)??(I) wherein Ra to Re are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
    Type: Grant
    Filed: December 13, 2005
    Date of Patent: April 22, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Markus Boehringer, Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Narendra Panday, Fabienne Ricklin
  • Publication number: 20080085928
    Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein L, R1, R2, m and n have the meaning given in claim 1 and which can be used in the form of pharmaceutical compositions.
    Type: Application
    Filed: September 24, 2007
    Publication date: April 10, 2008
    Inventors: Wolfgang Haap, Paul Hebeisen, Eric Kitas, Philipp Kohler, Holger Kuehne, Armin Ruf